Nuvectis Pharma (NVCT) appoints Juan Sanchez, MD to its Board of Directors

Rhea-AI Filing Summary

Nuvectis Pharma, Inc. filed a current report to disclose that its Board of Directors appointed Juan Sanchez, MD as a new director on September 22, 2025. He will serve on the Board until his term expires at the 2026 annual meeting of stockholders, when he is expected to stand for election by stockholders.

The company states that Dr. Sanchez has no arrangements or understandings with any other person related to his appointment, no family relationships with existing directors or executive officers, and no material interests in related-party transactions as described under Item 404(a) of Regulation S-K. Nuvectis announced his appointment in a press release dated September 25, 2025, which is included as an exhibit to the report.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 09/25/2025 - 08:23 AM Learn about SEC filing dates

FAQ

What board change did Nuvectis Pharma (NVCT) disclose in this 8-K?

Nuvectis Pharma disclosed that its Board of Directors appointed Juan Sanchez, MD as a new director effective September 22, 2025.

How long will Juan Sanchez, MD serve on the Nuvectis Pharma (NVCT) board?

Dr. Sanchez will serve as a director until his term expires at the 2026 annual meeting of stockholders, when he will stand for election by stockholders.

Does Juan Sanchez, MD have any related-party or family relationships with Nuvectis Pharma (NVCT)?

The company states that Dr. Sanchez has no arrangements or understandings with any person regarding his appointment, no family relationships with any director or executive officer, and no material interest in transactions covered by Item 404(a) of Regulation S-K.

How did Nuvectis Pharma (NVCT) announce the appointment of Juan Sanchez, MD?

Nuvectis announced Dr. Sanchez’s appointment in a press release dated September 25, 2025, which is filed as Exhibit 99.1 to the report.

What exhibits are included with this Nuvectis Pharma (NVCT) 8-K filing?

The filing includes Exhibit 99.1, the press release announcing Dr. Sanchez’s appointment, and Exhibit 104, the cover page interactive data file in iXBRL format.

Who signed the Nuvectis Pharma (NVCT) 8-K related to the new director appointment?

The report was signed on behalf of Nuvectis Pharma, Inc. by Ron Bentsur, the company’s Chairman, Chief Executive Officer and President, dated September 25, 2025.

false 0001875558 0001875558 2025-09-22 2025-09-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 22, 2025

Nuvectis Pharma, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation) 001-41264
(Commission File Number) 86-2405608
(IRS Employer Identification No.)

1 Bridge Plaza Suite 275

Fort Lee, NJ 07024

(Address of Principal Executive Offices)

(201) 614-3150

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of Class	Trading Symbol(s)	Exchange Name
Common Stock	NVCT	Nasdaq Capital Market

¨	Written communications pursuant to Rule 425 under the Securities Act.
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
¨	Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 22, 2025, the Board of Directors (the “Board”) of Nuvectis Pharma, Inc. (the “Company”) appointed Juan Sanchez, MD, to the Board. Dr. Sanchez will serve as a director until his term expires at the 2026 annual meeting of stockholders, at which time he will stand for election by the Company’s stockholders.

Dr. Sanchez has (i) no arrangements or understandings with any other person pursuant to which he was appointed to as a director, and (ii) no family relationship with any director or executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer.

Dr. Sanchez has no direct or indirect material interest in any transaction or series of similar transactions contemplated by Item 404(a) of Regulation S-K.

The Company announced Dr. Sanchez’s appointment via press release on September 25, 2025. A copy of the press release is being filed as Exhibit 99.1 and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit
Number		Description
99.1		Press release issued by Nuvectis Pharma, Inc., dated September 25, 2025.
104		Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Nuvectis Pharma, Inc.
	(Registrant)
Date: September 25, 2025
	By:	/s/ Ron Bentsur
		Ron Bentsur
		Chairman, Chief Executive Officer and President